Biologics “Switching” Common among Canadian Rhinology Patients with CRSwNP June 6, 2025 Switching biologics for CRSwNP is frequent in Canadian rhinology; the most common switch is from mepolizumab to dupilumab, with inadequate CRSwNP control driving the switch.